Cytosponge-trefoil factor 3 versus usual care to identify Barrett's oesophagus in a primary care setting: a multicentre, pragmatic, randomised controlled trial
Top Cited Papers
Open Access
- 1 August 2020
- journal article
- research article
- Published by Elsevier BV in The Lancet
- Vol. 396 (10247), 333-344
- https://doi.org/10.1016/s0140-6736(20)31099-0
Abstract
No abstract availableKeywords
Funding Information
- National Institute for Health Research
- Cancer Research UK
This publication has 30 references indexed in Scilit:
- British Society of Gastroenterology guidelines on the diagnosis and management of Barrett's oesophagusGut, 2013
- Variation in gastroscopy rate in English general practice and outcome for oesophagogastric cancer: retrospective analysis of Hospital Episode StatisticsGut, 2013
- Health Benefits and Cost Effectiveness of Endoscopic and Nonendoscopic Cytosponge Screening for Barrett's EsophagusGastroenterology, 2013
- Management of High-Grade Dysplasia and Intramucosal Adenocarcinoma in Barrett's EsophagusClinical Gastroenterology and Hepatology, 2012
- American Gastroenterological Association Technical Review on the Management of Barrett's EsophagusGastroenterology, 2011
- American Gastroenterological Association Medical Position Statement on the Management of Barrett's EsophagusGastroenterology, 2011
- Esophageal Adenocarcinoma Incidence: Are We Reaching the Peak?Cancer Epidemiology, Biomarkers & Prevention, 2010
- Radiofrequency Ablation in Barrett's Esophagus with DysplasiaThe New England Journal of Medicine, 2009
- Burden of Digestive Diseases in the United States Part I: Overall and Upper Gastrointestinal DiseasesGastroenterology, 2009
- Symptomatic Gastroesophageal Reflux as a Risk Factor for Esophageal AdenocarcinomaThe New England Journal of Medicine, 1999